ERBB2 and neoplasm: This study aimed to construct immunoapoptotic molecules by fusing anti‐HER‐2 scFv as a binding domain with DFF40 or tandem‐repeat Cytc (3Cytc) and evaluate the anti‐tumour efficacy of these constructs.